FDA's Henney Will Need To Tackle FY 2000 Budget To Address Staffing Levels
This article was originally published in The Gray Sheet
One of the first major challenges facing FDA Commissioner Jane Henney will be the development of an agency budget for fiscal year 2000 that addresses what officials call a "growing shortfall" of resources.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.